Abstract
Serum levels of interleukin-1 (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were measured preoperatively in 24 patients with colorectal cancer. IL-1β was not elevated, IL-6 and IL-8 were markedly elevated, and GM-CSF was slightly elevated. TNF-α was not detected in most patients. Serum IL-6 levels correlated closely with serum IL-8 levels and with serum carbohydrate antigen (CA) 19-9 levels. Serum IL-6 levels were significantly higher in patients whose tumors exceeding 5.0 cm in diameter or spreading circumferentially. Serum IL-8 levels showed significant differences according to histological type, being lower in well differentiated adenocarcinoma compared to other types. Serum levels of IL-6 and IL-8 were significantly higher in patients with liver metastasis than in those without liver metastasis and serum levels of both these cytokines were also significantly higher in patients with lung metastasis than in those without lung metastasis. These results suggest that IL-6 and IL-8 may play an important role in the hematogenous metastasis of colorectal cancer.
Similar content being viewed by others
References
Balkwill FR, Burke F. The cytokine network. Immunol Today 1989;9:299–304.
O'Garra A. Interleukins and the immune system 2. Lancet 1989;I:1003–1005.
Arai K, Lee F, Miyajima A, et al. Cytokines: Coordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59:783–836.
Dinarello CA. Interleukin-1 and the pathogenesis of the acutephase response. N Engl J Med 1984;311:1413–1418.
Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470–474.
Tracey KJ, Fong Y, Hesse D, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987;330:662–664.
Nijsten MWN, De Groot ER, Ten Duis HJ, et al. Serum levels of interleukin-6 and acute phase response. Lancet 1987;II:921.
Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;I:355–357.
Damas P, Reuter A, Gysen P, et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989;17:975–978
Nishimoto N, Yoshizaki K, Tagoh H, et al. Elevation of serum interleukin-6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 1989;50: 399–401
Leser HG, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991;101:782–785
Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992;215:356–362
Sakamoto K, Egami H, Yoshimura R, et al. Colony-Stimulating factor producing carcinoma of the gallbladder. Jpn J Clin Oncol 1986;16:87–96
Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83–85
Van Meir E, Sawamura Y, Diserens AC, et al. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 1990;50:6683–6688
Watson JM, Sensintaffar JL, Berek JS, et al. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990;50:6959–6965
Siegall CB, Schwab G, Nordan RP, et al. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990;50:7786–7788
Takenawa J, Kaneko Y, Fukumoto M, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991;83:1668–1672
Naylor MS, Stamp GWH, Foulkes WD, et al. Tumor necrosis factor and its receptors in human ovarian cancer. J Clin Invest 1993;91:2194–2206
Scuderi P, Lam KS, Ryan KJ, et al. Raised serum levels of tumor neerosis factor in parasitic infections. Lancet 1986;II: 1364–1365
Teppo AM, Maury CPJ. Radioimmunoassay of tumor necrosis factor in serum. Clin Chem 1987;33:2024–2027
Balkwill F, Burke F, Talbot D, et al. Evidence for tumor neerosis factor eachectin production in cancer. Lancet 1987;II: 1229–1232
Socher SH, not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 1988;80:595–598
Fearon KCH, McMillan DC, Preston T, et al. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991;213:26–31
Japanese Research Society for Cancer of Colon and Rectum. General rules for clinical and pathological studies on cancer of colon, rectum, and anus. 4th ed. Tokyo: Kanehara Shuppan, 1985
American Joint Committee on Cancer, Manual for staging of cancer. 3rd ed, Philadelphia: JB Lippincott, 1987
Hermanek P, Sobin LH (eds) TNM classification of malignant tumors (International Union Against Cancer). 4th ed. Berlin: Springer, 1987
Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102:514–519
Izzo RS, Witkon K, Chen AI, et al. Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am J Gastroenterol 1992;87:1447–1452
Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992; 103:1587–1595
Hyams JS, Fitzgerald JE, Treem WR, et al. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993;104: 1285–1292
Shalaby MR, Waage A, Aarden L, et al. Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol 1989;53:488–498
Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/ tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989;170: 1627–1633
Isshiki H, Akira S, Tanabe O, et al. Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive clement in the IL-6 gene. Mol Cell Biol 1990;10:2757–2764
Matsushima K, Oppenheim JJ. Interleukin-8 and MCAF: Novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1989;1:1–12
Natali P, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990;50:1271–1278
Tsujisaki M, Imai K, Hirata H, et al. Detection of circulating adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol 1991;85:3–8
Takada A, Ohmori K, Yoneda T, et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 1993;53:354–361
Dejane E, Bertocchi F, Bortolami MC, et al. Interleukin 1 promotes tumor cell adhesion to cultured human endothelial cells. J Clin Invest 1988;82:1466–1470
Larson CG, Anderson AD, Apella E, et al. The neutrophilactivating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989;243:1464–1466
Strieter RM, Kunkel SL, Showell HL, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β. Science 1989;243:1467–1469
Paccaud JP, Shifferli JA, Baggiolini M. NAP-1/IL-8 induces upregulation of CR1 receptors in human neutrophil leukocytes. Biochem Biophys Res Commun 1990;166:187–192
Detmers PA, Lo SK, Olsen-Egbert E, et al. Neutrophil activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med 1990;171:1152–1162
Takeda A, Ohmori K, Takahashi N, et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochem Biophys Res Commun 1991; 179:713–719
Berg EL, Robinson MK, Mansson O, et al. A carbohydrate domain common to both sialyl Lea and sialyl Lex is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem 1991;266:14869–14872
Fabian I, Baldwin GC, Golde DW, et al. Biosynthetic granulocyte-macrophage colony-stimulating factor enhances neutrophil cytotoxicity toward human leukemia cells. Leukemia 1987;1:613–617
Grabstein KH, Urdal DL, Tushinski RJ, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986;232:506–508
Takeda K, Hatakeyama K, Tsuchiya Y, et al. A correlation between GM-CSF gene expression and metastases in murine tumors. Int J Cancer 1991;47:413–420
Young MRI, Lozano Y, Coogan M, et al. Stimulation of the metastatic properties of Lewis lung carcinoma cells by autologous granulocyte-macrophage colony-stimulating factor. Int J Cancer 1992;50:628–634
Takeda K, Fujii N, Nitta Y, et al. Murine tumor cells metastasizing selectively in the liver: Ability to produce hepatocyteactivating cytokines interleukin-1 and/or-6. Jpn J Cancer Res 1991;82:1299–1308
Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666–3670
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ueda, T., Shimada, E. & Urakawa, T. Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29, 423–429 (1994). https://doi.org/10.1007/BF02361238
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02361238